Immune Profile of the Neuro-2a Mouse Neuroblastoma Model by Flow Cytometry

Neuroblastoma is an extracranial tumor that arises from neural crest-derived progenitor cells. It is the most prevalent solid tumor in childhood and the most common tumor in infants less than one year of age. With up to 800 new cases diagnosed each year, in spite of aggressive multi-modal therapeutic approaches, the 5-year survival rate in patients with high-risk neuroblastoma remains poor at <50 percent.1 This necessitates novel therapies that improve clinical outcome. To this end, the development of drugs that boost host anti-tumor responses to overcome the immunosuppressive environment in neuroblastoma has drawn attention.

Continue reading